An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)

NCT05183802 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Bardet-Biedl Syndrome (BBS)
Obesity

Interventions

DRUG: Setmelanotide, administered subcutaneously [SC], once daily.

Sponsor

Rhythm Pharmaceuticals, Inc.